A selective mGlu1a
receptor antagonist, with an IC50
value of 8.8 μ
M for blockade of quisqualate-induced phosphoinositide hydrolysis vs. > 100 μ
M for mGlu5a
, and negligible action on group II and III receptors. Also available as part of the Group I mGlu Receptor Tocriset™
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of Eli Lilly and Company
Synthesis of S-[3-(4(5)-imidazolyl)propyl]-N-[2-(4-[125I]-iodophenylethyl]isothiourea sulfate [125I]-iodophenpropit), a new probe for histamine H3 receptor binding sites.
Menge et al.
J.Labelled Comp.Radiopharm. XXXI, 1992;10:781
Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 recept
Bruno et al.
Anticonvulsant actions of LY 367385 ((+)-methyl-4-carboxyphenylglycine), and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid).
Chapman et al.
Reduction of sensory and metabotropic glutamate receptor responses in the thalamus by the novel metabotropic glutamate receptor-1-selective antagonist S-2-methyl-4-carboxy-phenylglycine.
Salt and Turner
The citations listed below are publications that use Tocris products. Selected citations for LY 367385 include:
Showing Results 1 - 10 of 31